Dissecting the Anti-Glioma Mechanisms of Shenqi Fuzheng Injection: A Network Pharmacology Approach

Study Background and Research Question

Malignant gliomas are among the most aggressive and therapeutically challenging brain tumors, accounting for up to 50% of primary intracranial neoplasms. Despite advances in surgery, chemotherapy, and radiotherapy, median survival remains dismal—often less than 17 months—due to rapid proliferation, invasive behavior, and early metastasis. Shenqi Fuzheng injection (SFI), a traditional Chinese medicine formulation comprising Codonopsis pilosula and Astragalus membranaceus, is clinically used as an adjuvant to chemotherapy, but its molecular mechanism against glioma was previously unclear.

The central research question addressed by the reference study is: Through which molecular pathways does SFI exert its anti-proliferative and anti-migratory effects on glioma cells, and can these mechanisms be systematically mapped using network pharmacology and experimental validation?

Key Innovation from the Reference Study

The study's primary innovation lies in the integration of network pharmacology with experimental biology to elucidate how SFI targets the SRC/PI3K/AKT signaling pathway in glioma cells. By combining computational predictions with multi-modal validation—spanning in vitro cell models and in vivo mouse models—the authors systematically charted the landscape of SFI's active components, their putative targets, and the downstream molecular events underpinning glioma suppression. This integrative approach advances the field by linking herbal pharmacology to defined oncogenic signaling nodes, offering a template for mechanism-driven anti-angiogenic compound discovery.

Methods and Experimental Design Insights

The investigation proceeded in two main stages:

• Network Pharmacology Analysis: The researchers identified 26 major bioactive SFI constituents and cross-referenced these with 3,343 known glioma-associated targets, revealing 79 overlapping targets. Network enrichment pinpointed the SRC/PI3K/AKT cascade as a convergence node.
• In Vitro and In Vivo Validation: Human glioma cell lines U87 and T98G were treated with SFI, with effects assessed using CCK-8 and EdU proliferation assays, plate cloning, scratch and Transwell migration assays, immunofluorescence, flow cytometry, and Western blot analysis of pathway markers. For in vivo relevance, GL261 cells were used to establish subcutaneous tumors in C57BL/6 mice, followed by SFI administration and evaluation through HE staining and immunohistochemistry.

This design enabled rigorous cross-validation of computational predictions with phenotypic and molecular endpoints.

Core Findings and Why They Matter

Key findings from the study include:

• SFI suppresses glioma cell proliferation and induces S-phase cell cycle arrest: Both U87 and T98G lines exhibited reduced proliferation and increased S-phase blockade upon SFI exposure.
• Migration and EMT inhibition: SFI treatment downregulated epithelial-mesenchymal transition (EMT) markers, reducing cellular motility and invasive potential.
• In vivo tumor growth suppression: SFI markedly inhibited tumor progression in GL261 xenografts, aligning with in vitro observations.
• SRC/PI3K/AKT pathway as a mechanistic axis: Network analysis and Western blotting confirmed that SFI exerts its anti-glioma effects by inhibiting SRC and downstream PI3K/AKT signaling, both well-established drivers of tumor growth, survival, and angiogenesis.

The identification of the SRC/PI3K/AKT axis as a critical mediator positions SFI as a prototypical multi-target angiogenesis inhibitor, providing a molecular rationale for its observed clinical benefits and guiding the rational design of adjunctive anti-angiogenic strategies in glioma.

Comparison with Existing Internal Articles

The present study's mechanistic clarity aligns closely with recent internal reviews. For example, one internal article outlines the anti-glioma effects of SFI via SRC/PI3K/AKT blockade, highlighting the translational value of network pharmacology in target identification. Another internal summary underscores SFI's anti-angiogenic and anti-proliferative actions, reinforcing the view that network-based approaches can inform the design of targeted therapies for aggressive tumors. These alignments support the reproducibility and broader relevance of the reference study’s findings within the context of tumor angiogenesis research.

Limitations and Transferability

While the dual network-experimental strategy is a strength, several limitations warrant attention:

• Complexity of SFI composition: The multi-component nature of SFI complicates attribution of effects to individual molecules.
• Model constraints: Although U87, T98G, and GL261 are established glioma models, their genetic backgrounds do not capture the full heterogeneity of human gliomas.
• Translational gap: The study stops short of clinical efficacy trials, and further work is needed to assess SFI’s pharmacokinetics, safety, and long-term outcomes in diverse patient populations.

Despite these caveats, the mechanistic insights provided can inform future studies targeting SRC, PI3K, AKT, and related angiogenic pathways across other tumor models.

Protocol Parameters

• SFI treatment in vitro: Apply SFI to U87 or T98G cells at optimized concentrations for 24–48 hours; monitor proliferation via CCK-8 and EdU assays.
• Migration assays: Use scratch or Transwell systems with SFI post-treatment for 24 hours to assess migration and invasion.
• In vivo validation: Inject GL261 cells subcutaneously into C57BL/6 mice, administer SFI at validated doses, and evaluate tumor growth by HE staining and immunohistochemistry after 2–4 weeks.
• Pathway analysis: Employ Western blot to quantify SRC, PI3K, and AKT phosphorylation status in treated vs. control samples.
• For novel anti-angiogenic compound screening, consider integrating a VEGF receptor inhibitor as a positive control or comparator.

Research Support Resources

To extend these findings or support related anti-angiogenic workflows, researchers can utilize selective VEGF receptor inhibitors for precise pathway dissection. For example, AAL-993 (SKU C3730) is a potent VEGF receptor inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3, with proven in vitro and in vivo anti-angiogenic activity. Its well-characterized selectivity profile facilitates reproducible assay development in tumor angiogenesis research. For detailed protocols and compound characteristics, consult the APExBIO resource page.